We are live on ! Find out more
ACHL

Achilles Therapeutics
ACHL

Delisted

ACHL was delisted on the 20th of March, 2025.

Back to rankings

28 hedge funds and large institutions have $58.3M invested in Achilles Therapeutics in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

50% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 6

12% more funds holding

Funds holding: 25 → 28 (+3)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

9% less capital invested

Capital invested by funds: $64.4M → $58.3M (-$6.07M)

Holders
28
Holders Change
+3
Holders Change %
+12%
% of All Funds
0.48%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
5
Increased
9
Reduced
6
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$936K
2
KHCM
Kettle Hill Capital Management
New York
+$370K
3
FA
Forefront Analytics
Pennsylvania
+$91.1K
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$48.3K
5
SEI Investments
SEI Investments
Pennsylvania
+$43.7K

Top Sellers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
-$588K
2
O
OrbiMed
New York
-$344K
3
Citadel Advisors
Citadel Advisors
Florida
-$69K
4
BlackRock
BlackRock
New York
-$20.6K
5
Renaissance Technologies
Renaissance Technologies
New York
-$17.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
SP
1
Syncona Portfolio
Guernsey
$25.1M – – –
RCM
2
RA Capital Management
Massachusetts
$11.3M – – –
BBA
3
Baker Bros. Advisors
New York
$5.86M – – –
AG
4
Artal Group
Luxembourg
$5.1M – – –
Point72 Asset Management
5
Point72 Asset Management
Connecticut
$4.76M +$936K +330,851 +19%
RG
6
Redmile Group
California
$3.63M – – –
KHCM
7
Kettle Hill Capital Management
New York
$844K +$370K +130,580 +54%
Axa
8
Axa
France
$646K +$6.23K +2,201 +0.8%
BlackRock
9
BlackRock
New York
$572K -$20.6K -7,291 -3%
Renaissance Technologies
10
Renaissance Technologies
New York
$183K -$17.5K -6,200 -7%
SEI Investments
11
SEI Investments
Pennsylvania
$88K +$43.7K +15,458 +66%
FA
12
Forefront Analytics
Pennsylvania
$72K +$91.1K +32,200 New
Geode Capital Management
13
Geode Capital Management
Massachusetts
$48K – – –
Balyasny Asset Management
14
Balyasny Asset Management
Illinois
$39K +$48.3K +17,059 New
Goldman Sachs
15
Goldman Sachs
New York
$30K -$232 -82 -0.6%
Bank of America
16
Bank of America
North Carolina
$21K -$7.82K -2,763 -22%
Morgan Stanley
17
Morgan Stanley
New York
$16K +$2.32K +819 +13%
UBS Group
18
UBS Group
Switzerland
$6K +$1.3K +458 +21%
EWM
19
Endurance Wealth Management
Rhode Island
$5K – – –
JP Morgan Chase
20
JP Morgan Chase
New York
$5K +$2.31K +815 +52%
O
21
OrbiMed
New York
$3.31K -$344K -121,594 -8%
CSS
22
Cubist Systematic Strategies
Connecticut
$2K +$1.13K +400 +58%
TRCT
23
Tower Research Capital (TRC)
New York
$2K +$2.22K +785 +3,738%
Acadian Asset Management
24
Acadian Asset Management
Massachusetts
$2K +$3.59K +1,268 New
Citigroup
25
Citigroup
New York
$1K -$34 -12 -2%
1
2

ACHL Hedge Fund Activity: Q3 2022 in Review

28 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Achilles Therapeutics (ACHL) for Q3 2022, worth a combined $58.3M — down 9.4% from $64.4M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new ACHL positions and 2 closed out — a net gain of 3 holders — while 9 added to existing stakes and 6 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $936K. The largest seller was Woodline Partners, exiting entirely with an estimated $588K sold.

  • 28 institutional investors held Achilles Therapeutics (ACHL) as of Q3 2022, up from 25 in Q2 2022.
  • Funds reported $58.3M of Achilles Therapeutics stock for Q3 2022, down 9.4% quarter-over-quarter.
  • 5 funds opened new Achilles Therapeutics positions in Q3 2022 and 2 closed out, a net change of +3 holders.
  • The largest Achilles Therapeutics buyer in Q3 2022 was Point72 Asset Management, an estimated $936K added.
  • The largest Achilles Therapeutics seller in Q3 2022 was Woodline Partners, an estimated $588K sold.

Based on aggregated 13F filings for Q3 2022.